Aquestive Therapeutics Prepares for FDA Approvals and Launches

Aquestive Therapeutics ( (AQST) ) has provided an announcement.

Aquestive Therapeutics has announced plans regarding the advancement of its product candidates, including Anaphylm, a sublingual film for epinephrine, and AQST-108, a topical gel for alopecia areata. The company is preparing for potential FDA approvals and market launches, which could significantly impact its market positioning and offer new alternatives in the treatment of these conditions.

The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.

Spark’s Take on AQST Stock

According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.

Aquestive Therapeutics faces significant financial and operational challenges, reflected in its low financial performance score. The company shows some potential through its strategic focus on Anaphylm, but current financial instability and technical indicators suggest caution. The valuation remains weak due to ongoing losses, impacting the overall score.

To see Spark’s full report on AQST stock, click here.

More about Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of innovative drug delivery systems. The company is known for its PharmFilm technology and is working on products like Anaphylm and AQST-108, targeting conditions such as anaphylaxis and alopecia areata.

Average Trading Volume: 1,433,426

Technical Sentiment Signal: Sell

Current Market Cap: $269.2M

For an in-depth examination of AQST stock, go to TipRanks’ Stock Analysis page.